UK consumers reduced their purchases of food and alcohol during the holiday season, with industry experts attributing this trend to the increasing popularity of weight loss injections. Despite reaching £19.6 billion in grocery sales for the four weeks leading up to December 27, a 2.5% increase from the previous year according to NielsenIQ, sales volume actually decreased by 0.2%.
Analysts in the retail sector suggest that the decline in food and alcohol sales is linked to the growing number of individuals opting for GLP-1 injections, which simulate a key hormone that signals fullness in the body. The NHS prescribes weight loss injections such as Mounjaro and Wegovy, and Ozempic for diabetes, with approximately 1.6 million UK adults reported to have used these treatments in the past year, as per University College London research.
Retail analyst Jonathan De Mello noted a noticeable impact of the Ozempic effect on grocery trends, with a significant rise in GLP-1 usage leading to a decline in year-on-year grocery volume among users. He emphasized the need for grocers to adapt their product offerings to align with the shift towards more mindful consumption patterns.
Consumer analyst Clive Black from Shore Capital highlighted the influence of GLP drugs on eating habits, particularly evident during the Christmas season through a decrease in grocery sales volume. Major retailers like Co-op, Marks & Spencer, and Iceland have responded by introducing smaller meal options to cater to changing consumer preferences.
The impact of weight loss injections on businesses is also evident, with Greggs’ CEO acknowledging the influence on sales growth. Chief executives from Tesco and Sainsbury’s expressed vigilance in monitoring consumer behaviors amidst the rise of weight loss medications, emphasizing the importance of adapting to evolving market dynamics.